United Kingdom Silico Protein Design Market Insight
Published: 30 July 2026 | Report Format: Electronic (PDF) | Author: Komal and Pranali
The United Kingdom Silico Protein Design Market is anticipated to grow at a CAGR of around 18.4% from 2025 to 2035, driven by increasing adoption of artificial intelligence in biologics discovery, expanding investments in computational drug development, and rising demand for precision protein engineering
United Kingdom Silico Protein Design Market Forecasts to 2035
- The United Kingdom Silico Protein Design Market Size was estimated at USD 0.19 Billion in 2025.
- The market is expected to grow at a CAGR of around 18.4% from 2025 to 2035.
- The United Kingdom Silico Protein Design Market Size is expected to reach USD 1.03 Billion by 2035.
Notable Insights for the United Kingdom Silico Protein Design Market
- Segmentation: Based on technology, AI-based protein design, molecular modelling, molecular docking, protein structure prediction, and de novo protein design collectively accounted for approximately 76% of the market share in 2025, supported by increasing adoption of computational biology across pharmaceutical and biotechnology research.
- Segmentation: Based on application, drug discovery, enzyme engineering, vaccine development, antibody engineering, and synthetic biology represented nearly 79% of the market in 2025, reflecting growing demand for faster biologic development and precision therapeutic research.
- Schrödinger, Inc. and Exscientia plc reported revenues of approximately USD 205.3 million and USD 36.3 million, respectively, in 2024, highlighting continued investment in AI-enabled drug discovery, computational chemistry platforms, and digital protein engineering technologies.
Download the eBook (ToC)
- Recursion Pharmaceuticals, Inc., Arzeda Corporation, and Generate Biomedicines continue expanding AI-driven protein engineering capabilities. Recursion Pharmaceuticals generated approximately USD 58.6 million in revenue during 2024, reinforcing its position in computational biology, machine learning-enabled therapeutic discovery, and precision medicine research.
Why Buy This Report
- Provides a comprehensive assessment of the United Kingdom Silico Protein Design Market, covering computational protein engineering trends, AI-enabled drug discovery, biologics development, and long-term growth opportunities.
- Delivers valuable insights into protein structure prediction, molecular simulation technologies, enzyme engineering, synthetic biology applications, and the evolving computational biology ecosystem across the United Kingdom.
- Assists biotechnology companies, pharmaceutical manufacturers, AI platform developers, contract research organizations, academic research institutes, investors, and policymakers in identifying emerging opportunities, evaluating competitive dynamics, and supporting strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Silico Protein Design Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Silico Protein Design Market
- Exscientia plc
- Isomorphic Labs
- DeepMind Technologies Limited
- Schrödinger, Inc.
- Generate Biomedicines
- Arzeda Corporation
- Recursion Pharmaceuticals, Inc.
- Evotec SE
- BenevolentAI
- LabGenius Ltd.
Recent Developments:
- In October 2024, Isomorphic Labs expanded its collaboration with Novartis to accelerate AI-driven protein design and drug discovery, combining advanced computational modelling with pharmaceutical research to speed the development of innovative therapeutics.
- In June 2024, Schrödinger, Inc. launched enhanced protein design capabilities within its computational drug discovery platform, enabling researchers to improve protein optimization, molecular modelling accuracy, and biologics development workflows.
Market Segmentation:
United Kingdom Silico Protein Design Market, By Technology
- AI-Based Protein Design
- Protein Structure Prediction
- Molecular Docking
- Molecular Dynamics Simulation
- De Novo Protein Design
- Protein Engineering Platforms
United Kingdom Silico Protein Design Market, By Application
- Drug Discovery
- Antibody Engineering
- Enzyme Engineering
- Vaccine Development
- Synthetic Biology
- Industrial Biotechnology
- Others
United Kingdom Silico Protein Design Market, By Deployment Mode
- Cloud-Based
- On-Premises
United Kingdom Silico Protein Design Market, By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
- Healthcare Research Organizations
- Others
United Kingdom Silico Protein Design Market, By Region
- England
- Scotland
- Wales
- Northern Ireland
Expert Views:
The United Kingdom Silico Protein Design Market is expected to witness robust growth through 2035 as artificial intelligence, computational biology, and structural bioinformatics become integral to biologics and therapeutic discovery. Increasing demand for faster protein engineering, precision medicine, and next-generation biologics is encouraging biotechnology firms and pharmaceutical companies to adopt advanced in silico design platforms. Continued collaboration between AI developers, life science organizations, and academic research institutes is expected to strengthen innovation, improve drug development efficiency, and create significant opportunities for protein engineering technology providers across the United Kingdom.
Author: Komal and Pranali By Decisions Advisors and Consulting